F2GMacclesfield, England, United Kingdom
Disclosure information not submitted.
371 - Olorofim for the treatment of Central Nervous System (CNS) invasive fungal infections (IFI) in patients with limited or no treatment options: a sub-analysis of an open-label, single-arm, Phase 2b trial (Study 32; NCT03583164)
Tuesday, October 21, 202512:40 PM - 12:45 PM US ET
